Covid-19 rebound phenomenon
Pro Research Analysisby 
Searched over 200M research papers
COVID-19 Rebound Phenomenon: Definitions and Incidence
The COVID-19 rebound phenomenon refers to the return or worsening of symptoms, or a resurgence in viral activity, after initial improvement or recovery from COVID-19. This can occur after stopping treatments such as corticosteroids or antiviral medications, or even in untreated cases. Studies have reported that the incidence of rebound varies, with about 7–13% of patients experiencing symptom or viral rebound after antiviral therapy, and similar rates observed in untreated controls, suggesting that rebound may be part of the natural course of the disease as well as a treatment-related effect 2310.
Rebound After Corticosteroid Therapy: Risk Factors and Clinical Features
Patients with severe respiratory failure are at higher risk for rebound after stopping corticosteroid therapy. Key laboratory markers—such as elevated soluble interleukin-2 receptor (sIL-2R), C-reactive protein (CRP), and lactate dehydrogenase (LDH)—are associated with a greater likelihood of rebound. A predictive model using age, oxygen requirement, lymphocyte count, and sIL-2R levels showed good accuracy in identifying patients at risk . Rebound typically occurs around 12 days after symptom onset, and administering corticosteroids for at least two weeks from symptom onset may help prevent this phenomenon .
Rebound After Antiviral Therapy: Nirmatrelvir-Ritonavir and Molnupiravir
Rebound has also been observed after antiviral treatments such as nirmatrelvir-ritonavir (Paxlovid) and molnupiravir. The incidence of rebound is similar between these two drugs, and about one-tenth of patients with mild-to-moderate COVID-19 experience rebound after antiviral therapy 25610. High initial symptom scores and lymphopenia (low lymphocyte count) are associated with a higher risk of rebound 210. The median time to rebound after antiviral therapy is about 5–12 days 210.
Rebound in Untreated and Hospitalized Patients
Viral rebound can also occur in patients who do not receive antiviral therapy, with some studies showing a higher incidence of rebound in untreated hospitalized patients compared to those who received antivirals (17.3% vs. 11.5%). Among severe cases, antiviral therapy reduced the rate of rebound, highlighting the importance of treatment in infection control . The timing of rebound is similar between treated and untreated groups, typically occurring about two weeks after diagnosis .
Mechanisms and Contributing Factors
The exact mechanisms behind COVID-19 rebound are not fully understood. It may be influenced by the natural course of the disease, immune response, and the timing or duration of therapy. Factors such as age, severity of illness, immune status (e.g., lymphopenia), and initial symptom burden play a role in the likelihood of rebound 1234+1 MORE. More research is needed to clarify the causes and to optimize prevention strategies .
Conclusion
The COVID-19 rebound phenomenon is a recognized clinical issue that can occur after corticosteroid or antiviral therapy, as well as in untreated patients. Risk factors include severe initial illness, high inflammatory markers, and immune suppression. While antiviral therapy can reduce rebound rates in severe cases, the phenomenon is not exclusive to any one treatment and may reflect the natural progression of COVID-19 in some patients. Ongoing research is essential to better understand and manage this phenomenon for improved patient outcomes 1234+3 MORE.
Sources and full results
Most relevant research papers on this topic
Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
Severe respiratory failure patients are at higher risk for rebound phenomenon after corticosteroid cessation, with sIL-2R, LDH, and CRP values useful for assessing the risk.
The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls.
Rebound after viral clearance or symptom resolution is higher than previously reported, but similar rates were observed in both nirmatrelvir plus ritonavir-treated and untreated COVID-19 patients.
DOI